A Randomized Controlled Trial to Compare a Mobile-Bearing Cementless and Cemented Unicompartmental Knee: Results of an Investigational Device Exemption Study in the United States.

J ArthroplastyMay 26, 2026 (epub)
Clinical ResearchOrthopedic Surgery

William G Hamilton, Roberta E Redfern, Mark A Klaassen et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial compared mobile-bearing cementless and cemented unicompartmental knee arthroplasties in 378 patients. The study found no significant difference in 2-year survivorship rates, with 94.0% for cementless and 97.5% for cemented implants (P = 0.19), indicating noninferiority of the cementless option.

Key findings

  • 2-year survivorship was 94.0% for cementless vs 97.5% for cemented implants (P = 0.19).
  • 5-year survivorship rates were 91.7% for cementless vs 95.6% for cemented (P = 0.24).
  • Radiographic success was 93.8% for cementless vs 97.4% for cemented (P = 0.19).
  • Knee Society function scores were similar: 89.9 for cementless vs 89.8 for cemented (P = 0.95).

Why it matters

The findings suggest that cementless unicompartmental knee arthroplasty can achieve comparable clinical and radiographic outcomes to cemented options, potentially offering a viable alternative for patient selection in knee arthroplasty.

Source

PubMed · PMID 42203123

Published in J Arthroplasty. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Orthopedic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.